The CDDF Diversity Initiative has officially entered Phase II. This next stage focuses on deepening our understanding of diversity in clinical research through targeted work packages that address key dimensions, including age, sex and gender, intrinsic and extrinsic factors, and study analysis. Collaborating with academic research groups, the initiative will describe oncology-relevant population descriptors and discuss the use of this data in the analysis and evaluation of clinical trial outcomes.
Phase II is progressing actively, with several work package meetings already having taken place, and preparations for the remaining sessions are underway.
-
WP1: Age and Co-morbidities – 06/05/2025
-
WP2: Sex and Gender – 27/06/2025
-
WP3: Extrinsic Factors – 01/09/2025
-
WP4: Intrinsic Factors – 10/10/2025
-
WP5: Study Analysis and Evaluation (Part 1) – 02/12/2025
-
WP6: Study Analysis and Evaluation (Part 2) – 19/01/2026
The initiative will conclude with a final face-to-face project meeting in Brussels on 05/03/2026, bringing together all stakeholders to review outcomes and next steps.
The work will culminate in the development and publication of a white paper to support the inclusion of representative populations in oncology clinical trials, with a direct impact on European patients.